Urgent Recall of Ramipril Batches Due to Amlodipine Mix-Up, Warns UK MHRA

Millions of patients relying on a widely prescribed blood pressure medication are being urged to immediately verify their prescriptions following a critical alert issued by UK regulators. The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that certain batches of ramipril—specifically 5mg packs manufactured by Crescent Pharma Limited—may have been incorrectly filled with amlodipine, a distinct type of blood pressure drug. This alarming mix-up, identified during routine quality checks, has triggered a nationwide recall and raised urgent concerns about patient safety.

The MHRA has specifically flagged batch number GR164099, which is printed on the outer carton of affected packs. Patients are advised to inspect both the carton and the blister strips inside. If the inner packaging is labelled 'amlodipine,' the medication should be returned to the dispensing pharmacy immediately. Conversely, packs containing correctly labelled ramipril tablets with the same batch number but no signs of mislabelling do not require action. The regulator has emphasized that the error likely occurred during the packaging process at Crescent Pharma's facility, which produces both medications.

While both ramipril and amlodipine are used to manage hypertension, they operate through fundamentally different mechanisms. Ramipril, an ACE inhibitor, works by blocking a hormone that constricts blood vessels, allowing them to relax and reduce strain on the heart. Amlodipine, a calcium channel blocker, prevents calcium from entering muscle cells in blood vessel walls, achieving a similar effect through a different biological pathway. The MHRA has stated that the risk of severe harm from inadvertently taking the wrong medication is low, but symptoms such as dizziness due to excessively low blood pressure could occur.

Healthcare professionals and pharmacies have been instructed to return any remaining stock from the affected batch to the manufacturer. Shareen Doak, deputy director of benefit–risk evaluation at the MHRA, has urged patients who suspect they may have ingested amlodipine by mistake to seek immediate medical attention. 'Take the leaflet and any remaining tablets with you to your pharmacy or GP practice,' she said. 'Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme to ensure thorough monitoring of this incident.'

Ramipril remains one of the UK's most commonly prescribed medications, with over 35 million prescriptions dispensed between 2024 and 2025. However, the drug has faced scrutiny in recent years due to its potential to cause a persistent, debilitating cough—a side effect that can take months to resolve. This issue is shared by other ACE inhibitors, including lisinopril and captopril, which can also lead to the accumulation of proteins in airways that cause irritation. The current recall adds another layer of complexity for patients and healthcare providers navigating the management of hypertension.

Authorities have stressed the importance of vigilance in this matter, with the MHRA reinforcing that no confirmed cases of harm have been reported so far. Nevertheless, the scale of the recall underscores the critical role of pharmaceutical quality control and the necessity of robust communication channels between regulators, healthcare professionals, and the public. Patients are advised to remain proactive in verifying their medications and to report any anomalies to their pharmacists or doctors without delay.